摘要
目前,新型冠状病毒感染已成为影响人类健康的重大公共卫生问题,而接种疫苗是预防新型冠状病毒感染最有效的手段。因此,在做好疫情常态化防控的同时,加快新型冠状病毒疫苗接种的速度、扩大接种范围、提高人群的疫苗接种率,已成为国际社会有效防控新型冠状病毒感染疫情的共识。肾移植受者是罹患新型冠状病毒感染的高危人群,该群体长期处于低免疫状态,因此存在新型冠状病毒疫苗免疫应答减弱、疫苗选择、使用方法、突破性感染等问题。本文基于已发表的国内外资料,就肾移植受者新型冠状病毒疫苗接种与预防的有关问题提出建议并形成专家共识,以供临床医生及卫生保健工作者参考。
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has become a major public health problem affecting human health,and vaccination is the most effective means of preventing SARS-CoV-2 infection.Therefore,besides implementing regular epidemic prevention and control,it has become the consensus of the international community for effective prevention and control of SARS-CoV-2 infection to accelerating the speed of SARS-CoV-2 vaccination,expanding the scope of vaccination,and improving the vaccination rate of the population.Kidney transplant recipients are at high risk of SARS-CoV-2 infection.This population has been in a low immune state for a long time,so there are problems such as reduced immunogenicity of SARS-CoV-2 vaccine,selection and use of vaccine,and breakthrough of infection.Based on the published international and domestic data,this paper provides recommendations and expert consensus on the relevant issues of SARS-CoV-2 vaccination and prevention in kidney transplant recipients for clinicians and health care workers to reference.
作者
无
林俊
张伟杰
薛武军
杨洋
张健
朱一辰
无;Lin Jun;Zhang Weijie;Xue Wujun(Branchof Organ Transplantation of Chinese Medical Association;Department of Urology,Af filiated Beijing Friendship,Capital Medical University,Beijing 100050,China;Institute of Organ Transplantation,Tongji Hospital,Tongji Medical College,Wuhan 430030;Department of Kidney Transplantation,The First Af filiated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
出处
《中华器官移植杂志》
CAS
2023年第1期6-16,共11页
Chinese Journal of Organ Transplantation
基金
国家自然科学基金(82000717)
北京市自然科学基金(7192043、7194250)
北京市医院管理中心"青苗计划"计划(QML20190106)。
关键词
肾移植
疫苗接种
新型冠状病毒
单克隆抗体
Kidney transplantation
Vaccine inoculation
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
Monoclonal antibody
